Anti-VEGF-A Antibody, clone 2C4 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 2C4 is a ZooMAb^® Rabbit recombinant monoclonal antibody that specifically detects Vascular endothelial growth factor A (VEGF-A).

Full-length mature recombinant human Vascular endothelial growth factor A (without the signal peptide).

Quality Control Testing

Evaluated by Western Blotting with recombinant Human VEGF-A (Non-denatured).

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected recombinant Human VEGF-A (Non-denatured).

Tested applications

Enzyme Immunoassay Analysis (ELISA): Various dilutions of this antibody detected recombinant Human VEGF-A in ELISA application.

Affinity Binding Assay: A representative lot of this antibody bound VEGF-A protein with a KD of 1.3 x 10-6 in an affinity binding assay.

Flow Cytometry Analysis: 1 μg from a representative lot detected VEGF-A in one million HeLa cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Evaluated by Western Blotting with recombinant Human VEGF-A (Non-denatured).

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected recombinant Human VEGF-A (Non-denatured).

Vascular endothelial growth factor A (UniProt: P15692; also known as VEGF-A, Vascular permeability factor, VPF) is encoded by the VEGFA (also known as VEGF) gene (Gene ID: 7422) in human. VEGF is a disulfide-linked homodimeric protein that acts as one of the most potent angiogenic factor to regulate vascular proliferation and permeability. It also acts as an anti-apoptotic factor for newly formed blood vessels. VEGF-A is a prototypical member of a family of related growth factors that includes placental growth factor (PLGF), VEGF-B, VEGF-C, and VEGF-D. It is synthesized with a signal peptide (aa 1-26), which is subsequently cleaved off to generate the mature form. Alternative splicing of a single VEGF gene generates multiple isoforms, including VEGF 121, 145, 165, 189, and 206, which differ in their molecular weights and in their ability to bind to cell-surface heparan sulfate proteoglycans. VEGF121 and VEGF165 are reported to be the most dominant forms expressed in all tumor cell lines investigated. VEGF121 is acidic and is freely secreted. However, VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. The biological effects of VEGF are mediated through two VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1), whose expression is largely, limited to the vascular endothelium. Although VEGF is essential for physiologic vascular homeostasis, it is also involved in the pathogenesis of tumor growth and metastasis, age-related macular degeneration, and diabetic and hypertensive retinopathy. VEGF expression is enhanced in response to hypoxia, oncogenes, and other cytokines, and is associated with poor prognosis in several types of cancer. This ZooMAbZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Apte, RS., et al. (2019). Cell. 176 (6); 1248-1264; Holmes, DIR., and Zachary, I. (2005). Genome Biol. 6(2); 209).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.